外泌体PD-L1在非小细胞肺癌免疫治疗的研究进展.pdfVIP

外泌体PD-L 1在非小细胞肺癌免疫治疗 的研究进展 【摘要】肿瘤免疫疗法在当前癌症治疗领域中愈来愈受瞩目 ，相关研究也层出不穷 。对于非小细胞肺癌 (non-small cell lung cancer, NSCLC )患者来说 ，近些年来 ，以程序性死亡受体 1 ( programmed cell death 1, PD-1 ) /程 序性死亡配体1 (programmed cell death ligand 1, PD-L1 )免疫抑制剂为代表的免疫检查点抑制剂(immune checkpoint inhibitors, ICIs )已经成为治疗恶性肿瘤的一种最具前景的治疗方案 。免疫检查点阻断治疗包括抗细胞毒T淋巴细胞 相关抗原4 ( cytotoxic T lymphocyte-associated antigen 4, CTLA-4 )单抗 、抗PD-1单抗和抗PD-L 1单抗 ，其中最被人熟知 的为PD-L1免疫疗法 。目前ICIs在临床治疗中取得了很不错的治疗效果 ，但有效率较低 ，因此我们希望获得更高的 治疗有效率 。近几年外泌体PD-L1在NSCLC免疫治疗中发挥了重要作用 。本文就肿瘤外泌体PD-L1蛋白对肿瘤微环 境的影响 、预测免疫治疗效果以及作为NSCLC免疫治疗的新型治疗策略作一综述。 【关键词】外泌体 ；PD-L1 ；肺肿瘤 ；免疫治疗 Research Advances of Immunotherapy of Exosome PD-L1 in Non-small Cell Lung Cancer Na WANG1, Xia SONG2 1rThe Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China; 2The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030000, China Corresponding author: Xia SONG, E-mail: songxia76@hotmail.co 【Abstract ] Cancer immunotherapy is increasingly popular in the field of cancer treatment, and related research is emerging. For patients with non-small cell lung cancer (NSCLC), in recent years, immune checkpoint inhibitors (ICIs) rep­ resented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants, have become one of the most promising treatments for malignant tumors. Immune checkpoint blockade therapy includes anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mAb, anti-PD-1 mAb and anti-PD-L1 mAb, with the best-known number of PD-L1 immunothera